利伐沙班在冠心病治疗中的研究进展

Research progress of rivaroxaban in the treatment of coronary heart disease

冠心病仍是世界上发病率和病死率最高的疾病之一。现有治疗方案下的冠心病仍有较高的心血管事件发生率。利伐沙班作为新型口服抗凝药物可以抑制FXa来减少心血管事件的发生。近年来,不断有研究探索利伐沙班在冠心病二级预防中的临床应用。本文将对利伐沙班在不同冠心病患者群体中的循证证据进行综述。

Coronary heart disease is still one of the highest morbidity and mortality in the world.Coronary heart disease under the existing treatment regimen still has a high incidence of cardiovascular events.Rivaroxaban as a new oral anticoagulant can inhibit FXa to reduce the incidence of cardiovascular events.In recent years,there have been studies to explore the clinical application of rivaroxaban in the secondary prevention of coronary heart disease.This article will review the evidence-based evidence of rivaroxaban in different groups of patients with coronary heart disease.